Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis (IPF)
IPF Longitudinal Natural History Study
This is a longitudinal observational cohort study of patients with idiopathic pulmonary fibrosis (IPF) conducted within the Assiut University IPF Research Program between 2022 and 2026.
- Trial name
- NCT07560189
- Where
- Egypt
- Volunteers
- 1,423 people
- Sponsor
- Assiut University
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Interstitial Lung Disease
Magnetic Resonance Imaging of the Lung: Non-Oncological Applications
Non-neoplastic pulmonary proliferative diseases are characterized by a complex interaction between proliferating lung cells and a variety of resident and infiltrating host cells, secreted factors, and extracellular matrix…
- Trial name
- NCT07493187
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two rare immune system disorders that cause the inflammation of blood vessels, or vasculitis.
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
- Trial name
- NCT00315393
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,046 people
- Sponsor
- University of Pennsylvania
Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
- Conditions
- Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease
- Trial name
- HCQ-chILD-EU (NCT02615938)
- Testing
- Hydroxychloroquine sulfate
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Matthias Griese
Post COVID-19 Diffuse Lung Disease
Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia.
- Trial name
- COLDSTER (NCT04657484)
- Testing
- Medium dose prednisolone, Low dose prednisolone
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III…
- Trial name
- NCT01619085
- Testing
- Nintedanib
- Where
- 173 sites in United States, Australia and 22 more
- Volunteers
- 752 people
- Sponsor
- Boehringer Ingelheim
Progressive Fibrosing Interstitial Lung Disease, Lung Transplant
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases
Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition.
- Conditions
- Progressive Fibrosing Interstitial Lung Disease, Lung Transplant, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT04857814
- Testing
- ADAMM- RSM Device
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Blood And Marrow Transplantation, Leukemia
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
The goal of this clinical research study is to learn if it is safe and feasible to transplant changed cord blood for patients with leukemia or lymphoma. Researchers also want to learn if this can help to control the disease.
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection
- Trial name
- NCT01471067
- Testing
- Melphalan, Fludarabine, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Interstitial Lung Disease, SARS-CoV-2 Infection
The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID.
Prospective observational study of hospitalised and non-hospitalised patients post- infection with SARS-CoV-2. The study aims to recruit 2000 individuals, with proven COVID-19, who were not hospitalised but presented to…
- Trial name
- UKILD (NCT05514522)
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female…
- Trial name
- NCT03502902
- Testing
- HEC 68498
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Rheumatoid Arthritis, Interstitial Lung Disease
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
- Trial name
- NCT07003451
- Testing
- Calprotectin Level
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with…
- Conditions
- Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis, Fibrosis, Lung Diseases, Interstitial
- Trial name
- NCT06383819
- Testing
- Longidaza®
- Where
- 30 sites in Russia
- Volunteers
- 392 people
- Sponsor
- NPO Petrovax
Idiopathic Pulmonary Fibrosis
Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF), a chronic fibrotic lung disease of unknown cause, is characterized by relentless progression, with a three-year mortality of up to 50%.
- Trial name
- IPF (NCT03480451)
- Testing
- Multi-Disciplinary Patient Centered Rehab and Education
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical College of Wisconsin
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic…
- Trial name
- MSC in IPF (NCT01385644)
- Testing
- Placental MSC
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- The Prince Charles Hospital
Drug Interactions
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
- Trial name
- NCT06717100
- Testing
- Nintedanib 150 MG [Ofev]
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PureTech
Combined Pulmonary Fibrosis and Emphysema Syndrome, Pulmonary Fibrosis
Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome
The combined pulmonary fibrosis and emphysema syndrome (CPFE) individualized by our group in 2005 is characterized by an often severe dyspnea, almost exclusive male predominance, and often major, profound impairment of gas…
- Conditions
- Combined Pulmonary Fibrosis and Emphysema Syndrome, Pulmonary Fibrosis, Emphysema, Healthy Subjects
- Trial name
- GENES-SEF (NCT02439528)
- Testing
- Genetic analysis
- Where
- 3 sites in France
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Idiopathic Pulmonary Fibrosis
Acute Effects of Oxygen Supplementation Among IPF Patients
Idiopathic pulmonary fibrosis (IPF) is a disease characterised with significant morbidity and poor prognosis. Dyspnoea and impaired exercise capacity are very common manifestations of the disease, and result in significant…
- Trial name
- NCT03688334
- Testing
- Oxygen 40 %
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- George Papanicolaou Hospital
Vasculitis, Wegener's Granulomatosis
Etanercept to Treat Wegener's Granulomatosis
This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis, a type of vasculitis (blood vessel inflammation).
- Trial name
- NCT00001901
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Interstitial Lung Disease, Interstitial Pneumonia
Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study
Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 by the Working Group of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) as interstitial pneumonia with some clinical and/or…
- Conditions
- Interstitial Lung Disease, Interstitial Pneumonia, Interstitial Fibrosis, Autoimmune Diseases
- Trial name
- NCT03870828
- Testing
- Bronchoalveolar lavage and taking bronchial mucosa samples, 6minute walk test, Arterial blood gas
- Where
- 7 sites in Italy, Poland
- Volunteers
- 210 people
- Sponsor
- Medical University of Silesia